Is ALX ONCOLOGY HOLDINGS INC (ALXO) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 3.4% / 30% | 44.1% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 3.4% / 33% | 44.1% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 6.7% / 33% | 86.5% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 3.4% / 33% | 44.1% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 6.7% / 33% | 86.5% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -145.7% | |
| Return on Assets (ROA) | -61.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$84M |
| Free Cash Flow | -$84M |
| Total Debt | $10M |
| Debt-to-Equity | 56.8 |
| Current Ratio | 2.1 |
| Total Assets | $59M |
Price & Trading
| Last Close | $2.04 |
| 50-Day MA | $2.02 |
| 200-Day MA | $1.35 |
| Avg Volume | 632K |
| Beta | 0.5 |
|
52-Week Range
$0.40
| |
About ALX ONCOLOGY HOLDINGS INC (ALXO)
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is ALX ONCOLOGY HOLDINGS INC (ALXO) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), ALX ONCOLOGY HOLDINGS INC is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is ALX ONCOLOGY HOLDINGS INC's debt ratio?
ALX ONCOLOGY HOLDINGS INC's debt ratio is 3.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 6.7%.
What are ALX ONCOLOGY HOLDINGS INC's key financial metrics?
ALX ONCOLOGY HOLDINGS INC has a market capitalization of $268M. Return on equity stands at -145.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.